387 related articles for article (PubMed ID: 21692778)
1. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
2. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
3. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
4. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
Hartung DM; Middleton L; Svoboda L; McGregor JC
CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
[TBL] [Abstract][Full Text] [Related]
5. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
Kwan P; Palmini A
Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
[TBL] [Abstract][Full Text] [Related]
6. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
Makus KG; McCormick J
Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
[TBL] [Abstract][Full Text] [Related]
7. The risks and costs of multiple-generic substitution of topiramate.
Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
[TBL] [Abstract][Full Text] [Related]
8. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
[TBL] [Abstract][Full Text] [Related]
9. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
Das S; Jiang X; Jiang W; Ting TY; Polli JE
Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
[TBL] [Abstract][Full Text] [Related]
10. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
Lessing C; Ashton T; Davis P
Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of generic versus brand-name antiepileptic medications.
Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
[TBL] [Abstract][Full Text] [Related]
12. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
[TBL] [Abstract][Full Text] [Related]
13. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.
Manjunath R; Paradis PE; Parisé H; Lafeuille MH; Bowers B; Duh MS; Lefebvre P; Faught E
Neurology; 2012 Oct; 79(18):1908-16. PubMed ID: 23077014
[TBL] [Abstract][Full Text] [Related]
14. Comparative stroke risk of antiepileptic drugs in patients with epilepsy.
Hsieh CY; Lai EC; Yang YH; Lin SJ
Epilepsia; 2013 Jan; 54(1):172-80. PubMed ID: 23030457
[TBL] [Abstract][Full Text] [Related]
15. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Zachry WM; Doan QD; Clewell JD; Smith BJ
Epilepsia; 2009 Mar; 50(3):493-500. PubMed ID: 18616554
[TBL] [Abstract][Full Text] [Related]
16. Economic burden associated with the use of generic antiepileptic drugs in the United States.
Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review.
Talati R; Scholle JM; Phung OP; Baker EL; Baker WL; Ashaye A; Kluger J; Coleman CI; White CM
Pharmacotherapy; 2012 Apr; 32(4):314-22. PubMed ID: 22461121
[TBL] [Abstract][Full Text] [Related]
18. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
[TBL] [Abstract][Full Text] [Related]
19. Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study.
Lai EC; Hsieh CY; Su CC; Yang YK; Huang CW; Lin SJ; Setoguchi S
Medicine (Baltimore); 2016 Aug; 95(35):e4481. PubMed ID: 27583857
[TBL] [Abstract][Full Text] [Related]
20. Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
Rascati KL; Richards KM; Johnsrud MT; Mann TA
Pharmacotherapy; 2009 Jul; 29(7):769-74. PubMed ID: 19558250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
